Dyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.

Proteins designed as drugs – the so-called biologics – sparked a medical revolution, but it has come at an extraordinary cost: less than 2% of Americans use these drugs, yet they account for 40% of total spend on prescription medications. Something’s got to give. Mark Emalfarb of Dyadic thinks that something is manufacturing, and his something is C1 – a protein manufacturing platform, and cell line that can produce biologics cheaper and faster than anything out there. Unconvinced? Give a listen.